AR116833A1 - Polipéptidos de fusión con glp-2 y su uso para el tratamiento y prevención de afecciones gastrointestinales - Google Patents

Polipéptidos de fusión con glp-2 y su uso para el tratamiento y prevención de afecciones gastrointestinales

Info

Publication number
AR116833A1
AR116833A1 ARP190103061A ARP190103061A AR116833A1 AR 116833 A1 AR116833 A1 AR 116833A1 AR P190103061 A ARP190103061 A AR P190103061A AR P190103061 A ARP190103061 A AR P190103061A AR 116833 A1 AR116833 A1 AR 116833A1
Authority
AR
Argentina
Prior art keywords
glp
fusion
gastrointestinal
polyeptides
affections
Prior art date
Application number
ARP190103061A
Other languages
English (en)
Inventor
Bettina Strack-Logue
Angela Norton
Original Assignee
Shire Nps Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Nps Pharmaceuticals Inc filed Critical Shire Nps Pharmaceuticals Inc
Publication of AR116833A1 publication Critical patent/AR116833A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen proteínas de fusión del GLP-2 con una región Fc de una inmunoglobulina. Las regiones de GLP-2 y Fc están separadas por un enlazador comprendido por aminoácidos. Se desvelan métodos de uso de las proteínas de fusión para tratar y prevenir las fistulas enterocutáneas, daño por radiación del tracto gastrointestinal, ictericia obstructiva, y síndrome de intestino corto.
ARP190103061A 2018-10-24 2019-10-24 Polipéptidos de fusión con glp-2 y su uso para el tratamiento y prevención de afecciones gastrointestinales AR116833A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862750001P 2018-10-24 2018-10-24

Publications (1)

Publication Number Publication Date
AR116833A1 true AR116833A1 (es) 2021-06-16

Family

ID=70331239

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103061A AR116833A1 (es) 2018-10-24 2019-10-24 Polipéptidos de fusión con glp-2 y su uso para el tratamiento y prevención de afecciones gastrointestinales

Country Status (10)

Country Link
US (1) US20210355187A1 (es)
EP (1) EP3870214A4 (es)
JP (1) JP2022512688A (es)
KR (1) KR20210082189A (es)
CN (1) CN112912099A (es)
AR (1) AR116833A1 (es)
AU (1) AU2019365212A1 (es)
CA (1) CA3114803A1 (es)
TW (1) TW202029979A (es)
WO (1) WO2020086741A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161087A1 (en) * 2003-05-29 2007-07-12 Wolfgang Glaesner Glp-1 fusion proteins
BRPI0617515A2 (pt) * 2005-10-24 2011-07-26 Centocor Inc mimeticorpos, polipeptÍdeos, composiÇÕes, mÉtodos e usos de glp-2
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
KR101825048B1 (ko) * 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
CN107987170B (zh) * 2016-10-27 2018-12-18 浙江道尔生物科技有限公司 一种用于治疗肠道疾病的融合蛋白
CA3071966A1 (en) * 2017-08-22 2019-02-28 Shire-Nps Pharmaceuticals, Inc. Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
MX2020004620A (es) * 2017-11-06 2020-10-12 Shire Nps Pharmaceuticals Inc Analogos y pepticuerpos de peptido 2 similar a glucagon (glp-2) para administracion antes, durante o despues de cirugia.

Also Published As

Publication number Publication date
CN112912099A (zh) 2021-06-04
AU2019365212A1 (en) 2021-04-29
US20210355187A1 (en) 2021-11-18
WO2020086741A1 (en) 2020-04-30
TW202029979A (zh) 2020-08-16
KR20210082189A (ko) 2021-07-02
JP2022512688A (ja) 2022-02-07
EP3870214A1 (en) 2021-09-01
CA3114803A1 (en) 2020-04-30
EP3870214A4 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
CO2019000931A2 (es) Polipéptidos modificados y usos de los mismos
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
ECSP19041447A (es) Variantes de il-2 para el tratamiento de enfermedades autoinmunes
CY1125716T1 (el) Αγωνιστες υποδοχεα glp-1 και χρησεις αυτων
EA201990229A1 (ru) Новый ботулинический нейротоксин и его производные
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
AR106144A1 (es) Un conjugado de proteína que comprende polipéptidos fisiológicos y una región fc inmunoglobulina
CL2020003255A1 (es) Proteínas de fusión que comprenden progranulina
CO2017009061A2 (es) Polipéptidos variantes de la enzima de degradación de inmunoglobulina g del s. pyogenes
PE20230404A1 (es) Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
AR078423A1 (es) Vacunas dirigidas a las celulas de langerhans
CO2018007203A2 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
CL2017001661A1 (es) Compuestos biciclicos fusionados para el tratamiento de una enfermedad.
PE20170665A1 (es) Anticuerpos anti-tau humanizados
CU20180062A7 (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
EA201691795A1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
PE20170471A1 (es) Polipeptidos receptores formulados y metodos relacionados
UY36021A (es) Proteìnas fc multimèricas
BR112018014668A2 (pt) multímeros de fc de igg recombinante
CL2017000053A1 (es) Anticuerpos de unión a protofibrillas aß
JP2016529227A5 (ja) 受容体媒介クリアランスが減少した、生理活性ポリペプチド単量体と免疫グロブリンＦｃ断片との結合体及びその製造方法
AR101456A1 (es) Inhibidores de cinasa c de proteína y métodos para usarse
AR107483A1 (es) Conjugado de enzimas terapéuticas
CL2019000640A1 (es) Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso.
BR112017009790A2 (pt) anticorpos direcionados ao anti-ang2 e métodos de uso